Supplementary Figures S1-S15 from Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Fig.1. Genomic alterations in paired T-ALL samples. Supplementary Fig. 2. Ex vivo sensitivity to dasatinib in T-ALL samples. Supplementary Fig. 3. The correlations between BCL2, BCL-XL (encoded by BCL2L1), and MCL1 expression levels and ex vivo sensitivity to the BH3 mimetics in the T-ALL cohort. Supplementary Fig. 4. BCL2 family member genes’ activities across T-ALL subtypes. Supplementary Fig. 5. The correlations of ex vivo sensitivity to other BH3 mimetics with the activities of their target genes Supplementary Fig. 6. Distributions of the average Bliss values for 40 T-ALL PDX samples treated with the combination of AZD4320 and dasatinib, asparaginase, nelarabine, or prednisolone. Supplementary Fig. 7. Synergistic potency (log10(α1)) of AZD4320 combined with asparaginase across T-ALL subtypes. Supplementary Fig. 8. MuSyC-derived metrics across T-ALL subtypes. Supplementary Fig. 9. In vivo efficacy of the combined BCL2/BCL-XL inhibition with dasatinib. Supplementary Fig. 10. AZD4320 and asparaginase synergize to induce cytotoxicity in Loucy. Supplementary Fig. 11. Mitochondrial bioenergetics in Loucy cells. Supplementary Fig. 12. Mitochondrial membrane potential in Loucy cells. Supplementary Fig. 13. TMRM staining of primary CD8+ T cells following AZD4320 and asparaginase treatment. Supplementary Fig. 14. The combination of AZD4320 and asparaginase induces caspase-dependent apoptotic cell death. Supplementary Fig. 15. Uncropped immunoblot images and corresponding gel images.